<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8100437</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6047</journal-id>
<journal-id journal-id-type="nlm-ta">Neurobiol Aging</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurobiol. Aging</journal-id>
<journal-title-group>
<journal-title>Neurobiology of aging</journal-title>
</journal-title-group>
<issn pub-type="ppub">0197-4580</issn>
<issn pub-type="epub">1558-1497</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27810638</article-id>
<article-id pub-id-type="pmc">5154819</article-id>
<article-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.10.005</article-id>
<article-id pub-id-type="manuscript">NIHMS822413</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Presenilin 1 mutations influence processing and trafficking of the ApoE receptor apoER2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moerman-Herzog</surname>
<given-names>Andrea M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN3">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Slaton</surname>
<given-names>Arthur</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barger</surname>
<given-names>Steven W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock AR 72205 USA</aff>
<aff id="A2"><label>2</label>Department of Neurobiology &amp; Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock AR 72205 USA</aff>
<aff id="A3"><label>3</label>Geriatrics Research, Education and Clinical Center, Central Arkansas Veterans Healthcare System, Little Rock AR 72205 USA</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Steve Barger, Department of Geriatrics, University of Arkansas for Medical Sciences, 4301 W. Markham, #807, Little Rock AR 72205, Tel: 501-526-5811, <email>bargerstevenw@uams.edu</email></corresp>
<fn fn-type="present-address" id="FN2">
<label>*</label>
<p>Present address: Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock AR 72205 USA; <email>wangwei@uams.edu</email></p>
</fn>
<fn fn-type="present-address" id="FN3">
<label>†</label>
<p>Present address: Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock AR 72205 USA; <email>moermanandream@uams.edu</email></p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>49</volume>
<fpage>145</fpage>
<lpage>153</lpage>
<!--elocation-id from pubmed: 10.1016/j.neurobiolaging.2016.10.005-->
<abstract id="Abs1">
<p id="P2">Presenilin (PS)-1 is an intramembrane protease serving as the catalytic component of γ-secretase. Mutations in the PS1 gene are the most common cause of familial Alzheimer’s disease (FAD). The LDL-receptor family member apoER2 is a γ-secretase substrate that has been associated with AD in several ways, including acting as a receptor for apolipoprotein E. ApoER2 is processed by γ-secretase into a C-terminal fragment (γ-CTF) that appears to regulate gene expression. FAD PS1 mutations were tested for effects on apoER2. PS1 mutation R278I showed impaired γ-secretase activity for apoER2 in the basal state or after exposure to Reelin. PS1 M146V mutation permitted accumulation of apoER2 CTFs after Reelin treatment, while no difference was seen between wild-type (WT) and M146V in the basal state. PS1 L282V mutation, combined with the γ-secretase inhibitor DAPT, greatly reduced the cell-surface levels of apoER2 without affecting total apoER2 levels, suggesting a defect in receptor trafficking. These findings indicate that impaired processing or localization of apoER2 may contribute to the pathogenic effects of FAD mutations in PS1.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>Schematic illustration of apoER2 processing at the membrane</title>
<p id="P3">
<graphic orientation="portrait" position="anchor" xlink:href="nihms822413u1.jpg"></graphic></p>
<p id="P38">ApoER2 is a type I transmembrane protein Cleavage by sheddase produces secreted apoER2 ectodomain and C-terminal fragment designated as “SR” (sheddase remnant). The latter is further processed within the transmembrane region by γ-secretase (presenilin 1, PS1). releasing C-terminal fragment (γ-CTF). DAPT, a γ-secretase inhibitor blocks the intramembrane cleavage. ApoER2 is bound by ligands such as ApoE and Reelin. the latter of which enhances proteolytic processing at both sites of apoER2 upon binding. We find that mutations in PS1 associated with inheritance of Alzheimer’s disease attenuate the cleavage of SR and the formation of γ-CTF.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer’s disease</kwd>
<kwd>apoER2</kwd>
<kwd>γ-secretase</kwd>
<kwd>lipoprotein receptor</kwd>
<kwd>presenilin</kwd>
<kwd>protein processing</kwd>
<kwd>protein trafficking</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>